- Home
- NRXS vs BMRA Comparison
NRXS vs BMRA Comparison
Compare NRXS & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- BMRA
- Stock Information
- Founded
- NRXS 2011
- BMRA 1971
- Country
- NRXS United States
- BMRA United States
- Employees
- NRXS N/A
- BMRA N/A
- Industry
- NRXS
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NRXS
- BMRA Health Care
- Exchange
- NRXS Nasdaq
- BMRA Nasdaq
- Market Cap
- NRXS 12.5M
- BMRA 11.2M
- IPO Year
- NRXS 2023
- BMRA N/A
- Fundamental
- Price
- NRXS $2.40
- BMRA $3.54
- Analyst Decision
- NRXS
- BMRA
- Analyst Count
- NRXS 0
- BMRA 0
- Target Price
- NRXS N/A
- BMRA N/A
- AVG Volume (30 Days)
- NRXS 36.9K
- BMRA 43.6K
- Earning Date
- NRXS 05-21-2025
- BMRA 04-14-2025
- Dividend Yield
- NRXS N/A
- BMRA N/A
- EPS Growth
- NRXS N/A
- BMRA N/A
- EPS
- NRXS N/A
- BMRA N/A
- Revenue
- NRXS $2,685,925.00
- BMRA $5,678,000.00
- Revenue This Year
- NRXS $138,883.78
- BMRA N/A
- Revenue Next Year
- NRXS $118.59
- BMRA N/A
- P/E Ratio
- NRXS N/A
- BMRA N/A
- Revenue Growth
- NRXS 9.18
- BMRA 5.01
- 52 Week Low
- NRXS $1.33
- BMRA $1.92
- 52 Week High
- NRXS $3.78
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- NRXS 65.87
- BMRA 39.79
- Support Level
- NRXS $1.33
- BMRA $3.18
- Resistance Level
- NRXS $2.09
- BMRA $3.93
- Average True Range (ATR)
- NRXS 0.36
- BMRA 0.47
- MACD
- NRXS 0.06
- BMRA -0.05
- Stochastic Oscillator
- NRXS 90.95
- BMRA 20.00
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.